Document:

Exhibit 10.3

                             STOCK PURCHASE WARRANT

THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
U.S. SECURITIES ACT OF 1933, AS AMENDED ("SECURITIES ACT"), OR ANY OTHER LAWS
AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER LAWS. NEITHER THE SECURITIES
EVIDENCED BY THIS CERTIFICATE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE
OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

                                                             February __, 2002

      Immtech International, Inc., a Delaware corporation ("Company") hereby
grants __________________________ ("Warrant Holder"), on the terms and
conditions set forth below, the right to purchase from the Company at any time
during the Exercise Period (hereinafter defined) up to fully-paid and
non-assessable shares of common stock, par value $0.01 per share, of the Company
(the "Common Stock"), as the same may be adjusted pursuant to Section 5 hereof,
at the Exercise Price (hereinafter defined).

Section 1. Definitions.

      "Aggregate Exercise Price" means the Exercise Price multiplied by the
total number of shares of Common Stock for which this Warrant is being
exercised.

      "Exercise Date" means the date this Warrant, the Exercise Notice and the
Aggregate Exercise Price are received by the Company.

      "Exercise Notice" means the form attached hereto as Exhibit A, duly
executed by the Warrant Holder.

      "Exercise Period" means the period beginning on the date the Warrant
Holder ceases to be a holder of Series A Preferred Stock, $0.01 par value, of
the Company ("Preferred Stock"), by conversion or redemption of his Series A
Preferred Stock pursuant to the terms of Certificate of Designation of the
Company of even date herewith (excluding transfers) and continuing until the
fifth anniversary of the date hereof; provided that if the Company exercises its
right to redeem this Warrant pursuant to Section 6 hereof, the Exercise Period
shall end on such date of redemption.

      "Exercise Price" is $6.00 per share of Common Stock, subject to the
adjustments set forth in Section 5 hereof.

      ""Fair Market Value" means the volume weighted average of the Company's
Common Stock for the 10 days preceding the date of issuance of this Warrant.

      "Warrant" means the right to purchase shares of Common Stock granted by
this warrant.

      "Warrant Shares" means shares of Common Stock issuable upon exercise of
this Warrant.

Section 2. Exercise. (a) This Warrant may be exercised by the Warrant Holder, in
whole or in part, at any time and from time to time during the Exercise Period
by the delivery to the Company at the address set forth in Section 11 hereof
this Warrant, the Exercise Notice duly executed by the Warrant Holder and the
Aggregate Exercise Price.

      (b) Subject to paragraph (c) below, payment of the Aggregate Exercise
Price shall be made by check or bank draft payable to the order of the Company
or by wire transfer to an account designated by the Company.

      (c) In the event that the Warrant is not exercised in full, the number of
Warrant Shares shall be reduced by the number of Warrant Shares for which the
Warrant is exercised, and the Company, at its expense, shall issue and deliver
to the Warrant Holder a new Warrant in the name of the Warrant Holder,
reflecting the reduced number of Warrant Shares.

Section 3. Delivery of Stock Certificates. (a) Subject to the terms and
conditions of this Warrant, promptly after the exercise of this Warrant in full
or in part, the Company will cause to be issued in the name of and delivered to
the Warrant Holder, or as the Warrant Holder may lawfully direct, a certificate
or certificates for the number of validly issued, fully paid and non-assessable
Warrant Shares to which the Warrant Holder is entitled upon such exercise,
together with any other stock or other securities or property (including cash,
where applicable) to which the Warrant Holder is entitled in accordance with the
provisions hereof.

      (b) This Warrant may not be exercised as to fractional shares of Common
Stock. In the event that the exercise of this Warrant would result in the right
to acquire a fractional share, then such fractional share shall be considered a
whole share and shall be added to the number of Warrant Shares issuable to the
Warrant Holder upon exercise of this Warrant.

Section 4. Representations, Warranties and Covenants of the Company. (a) The
Company will take all necessary action as may be required and permitted for the
legal and valid issuance of this Warrant and the Warrant Shares to the Warrant
Holder.

      (b) The Warrant Shares, when issued in accordance with the terms hereof,
will be duly authorized and, when paid for or issued in accordance with the
terms hereof, will be validly issued, fully paid and non-assessable.

      (c) The Company has authorized and reserved for issuance to the Warrant
Holder the requisite number of shares of Common Stock to be issued pursuant to
this Warrant. The Company will at all times reserve and keep available, solely
for issuance and delivery as Warrant Shares hereunder, such shares of Common
Stock as shall from time to time be issuable as Warrant Shares, and will
accordingly adjust the number of such shares of Common Stock promptly upon the
occurrence of any of the events specified in Section 5 hereof.

Section 5. Anti-Dilution. The Exercise Price and, accordingly, the number of
Warrant Shares issuable upon exercise of the Warrant, are subject to adjustment
from time to time in accordance with this Section 5.

      (a) Issuances of Common Stock or Convertible Securities. If the Company,
at any time prior to January 1, 2003, issues shares of its Common Stock or
rights, options, warrants or convertible or exchangeable securities entitling
the holders thereof to purchase or otherwise acquire shares of Common Stock
("Common Stock Equivalents") at a price per share less than the Exercise Price
in effect immediately prior to such issuance ("Triggering Issue"), then in each
such case the Exercise Price, except as hereinafter provided, shall be lowered
so as to be equal to an amount determined by multiplying such Exercise Price by
a fraction:

            (i) the numerator of which shall be (x) the number of shares of
      Common Stock "outstanding" (as hereinafter defined) immediately prior to
      the issuance of such additional shares of Common Stock or Common Stock
      Equivalents (calculated on a fully-diluted basis assuming the conversion
      of all then presently exercisable Common Stock Equivalents), plus (y) the
      number of shares of Common Stock which the net aggregate consideration, if
      any, received by the Company for the total number of such additional
      shares of Common Stock or Common Stock Equivalents so issued in such
      Triggering Issue would purchase at the Exercise Price in effect
      immediately prior to such issuance,

            (ii) the denominator of which shall be (x) the number of shares of
      Common Stock outstanding immediately prior to the issuance of such
      additional shares of Common Stock or Common Stock Equivalents (calculated
      on a fully-diluted basis assuming the exercise or conversion of all then
      presently exercisable Common Stock Equivalents), plus (y) the number of
      such additional shares of Common Stock so issued in such Triggering Issue
      (assuming the exercise or conversion of all Common Stock Equivalents
      issued in such Triggering Issue), and

            (iii) in no event, however, shall the Exercise Price be less than
      Fair Market Value.

      "Outstanding" when used with reference to Common Stock or any other stock
      of the Company having the right to participate in the distribution of
      dividends (as and when declared) and assets (upon liquidation of the
      Company) (collectively, the "Shares") means, at any date as of which the
      number of Shares is to be determined, all issued and outstanding Shares,
      and shall include all Shares issuable in respect of outstanding rights,
      options, warrants or convertible or exchangeable securities in such
      Shares; provided, however, that "Outstanding" shall not refer to any such
      Shares then directly or indirectly owned or held by or for the account of
      the Company.

      (b) Issuances of Warrants, Options and Purchase Rights to Common Stock or
Convertible Securities. For the purposes of this Section 5, the issuance of any
Common Stock Equivalent shall be deemed an issuance of Common Stock with respect
to adjustments in the Exercise Price if the Net Consideration Per Share (as
hereinafter determined) which may be received by the Company for such Common
Stock shall be less than the Exercise Price in effect at the time of such
issuance. Any obligation, agreement or undertaking to issue Common Stock
Equivalents at any time in the future shall be deemed to be an issuance at the
time such obligation, agreement or undertaking is made or arises. No adjustment
of the Exercise Price shall be made under this Section 5 upon the issuance of
any shares of Common Stock which are issued pursuant to the exercise, conversion
or exchange of any Common Stock Equivalents to the extent any adjustment shall
previously have been made upon the issuance of any such Common Stock Equivalents
as above provided.

            (i) Adjustments for Cancellation or Expiration of Common Stock
      Equivalents. Should the Net Consideration Per Share of any such Common
      Stock Equivalents be adjusted from time to time, then, upon the
      effectiveness of each such change, the Exercise Price will be that which
      would have been obtained (x) had the adjustments made upon the issuance of
      such Common Stock Equivalents been made upon the basis of the actual Net
      Consideration Per Share of such securities, and (y) had the adjustments
      made to the Exercise Price since the date of issuance of such Common Stock
      Equivalents been made to such Exercise Price as adjusted above. Any
      adjustment of the Exercise Price with respect to this Section 5(b) which
      relates to any Common Stock Equivalent shall be disregarded if, as, and
      when such Common Stock Equivalent expires or is canceled without being
      exercised, or is repurchased by the Company at a price per share at or
      less than the original purchase price, so that the Exercise Price
      effective immediately upon such cancellation or expiration shall be equal
      to the Exercise Price that would have been in effect had the expired or
      canceled Common Stock Equivalent not been issued.

            (ii) For purposes of this paragraph, the "Net Consideration Per
      Share" means the amount equal to the total amount of consideration, if
      any, received by the Company for the issuance of such Common Stock
      Equivalents, plus the minimum amount of consideration, if any, payable to
      the Company upon exercise, or conversion or exchange thereof, divided by
      the aggregate number of shares of Common Stock that would be issued if all
      such Common Stock Equivalents were exercised, exchanged or converted. The
      Net Consideration Per Share which may be received by the Company shall be
      determined in each instance as of the date of issuance of Common Stock
      Equivalents without giving effect to any possible future price adjustments
      or rate adjustments which may be applicable with respect to such Common
      Stock Equivalents.

      (c) Stock Dividends for Holders of Capital Stock Other Than Common Stock.
In the event that the Company shall make or issue, or shall fix a record date
for the determination of holders of any capital stock of the Company other than
holders of Common Stock entitled to receive a dividend or other distribution
payable in Common Stock or securities of the Company convertible into or
otherwise exchangeable for shares of Common Stock of the Company, then such
Common Stock or other securities issued in payment of such dividend shall be
deemed to have been issued for no consideration, except for (i) dividends
payable in shares of Common Stock payable pro rata to holders of Series A
Preferred Stock and to holders of any other class of stock (whether or not paid
to holders of any other class of stock), or (ii) with respect to the Series A
Preferred Stock, dividends payable in shares of Common Stock or Series A
Preferred Stock.

      (d) Consideration Other than Cash. For purposes of this Section 5, if a
part or all of the consideration received by the Company in connection with the
issuance of shares of the Common Stock or the issuance of any of the securities
described in this Section 5 consists of property other than cash, such
consideration shall be deemed to have a fair market value as is reasonably
determined in good faith by the Board of Directors of the Company.

      (e) Exceptions to Anti-dilution Adjustments. The provisions of this
Section 5 shall not apply to any Common Stock issued, issuable or deemed
outstanding (i) pursuant to the Company's stock option plans and employee stock
purchase plans, (ii) in connection with (a) the exercise of the Warrants granted
to Series A Preferred Stockholders, (b) Common Stock issued as dividends to
Series A Preferred Stockholders or (c) pursuant to the terms of any existing
class or series of debentures, stock or any other options, warrants or other
convertible securities, outstanding on the date hereof, (iii) in connection with
bank credit agreements and equipment and/or land lease lines with a non-equity
financing purpose and (iv) in connection with an acquisition, merger,
partnering, licensing or strategic transactions.

      (f) Extraordinary Common Stock Event. Upon the happening of an
Extraordinary Common Stock Event (as hereinafter defined), the Exercise Price
(and all other adjustments set forth above) shall, simultaneously with the
happening of such Extraordinary Common Stock Event, be adjusted by multiplying
the Exercise Price by a fraction, the numerator of which shall be the number of
shares of Common Stock outstanding immediately prior to such Extraordinary
Common Stock Event and the denominator of which shall be the number of shares of
Common Stock outstanding immediately after such Extraordinary Common Stock
Event, and the product so obtained shall thereafter be the Exercise Price. The
Exercise Price, as so adjusted, shall be readjusted in the same manner upon the
happening of any successive Extraordinary Common Stock Event or Events. An
"Extraordinary Common Stock Event" means (i) the issue of additional shares of
Common Stock as a dividend or other distribution on outstanding shares of Common
Stock, (ii) a subdivision of outstanding shares of Common Stock into a greater
number of shares of Common Stock, or (iii) a combination or reverse stock split
of outstanding shares of Common Stock into a smaller number of shares of the
Common Stock.

      (g) Capital Reorganization or Reclassification. If the Common Stock
issuable upon the conversion of the Series A Preferred Stock shall be changed
into the same or different number of shares of any class or classes of capital
stock, whether by Reorganization or otherwise (other than a subdivision or
combination of shares or stock dividend provided for elsewhere in this Section
5, or the sale of all or substantially all of the Company's capital stock or
assets to any other person), then and in each such event the holders of the
Series A Preferred Stock shall have the right thereafter to convert such shares
into the kind and amount of shares of capital stock and other securities and
property receivable upon such Reorganization or other change by the holders of
the number of shares of Common Stock into which such shares of Series A
Preferred Stock might have been converted immediately prior to such
reorganization, recapitalization, reclassification or change, all subject to
further adjustment as provided herein.

Section 6. Redemption. At any time after the first anniversary of the date
hereof if the Company's Common Stock closes above 200% of the Exercise Price for
20 consecutive "trading days" (days the principal exchange on which the Common
Stock is traded is open for business or, if the Common Stock is no longer traded
on an exchange, business days), the Company may redeem any unexercised portion
of this Warrant for a redemption fee of $0.10 per share ("Redemption Fee"). At
least 20 trading days prior to the date fixed for the redemption the Company
shall mail written notice to each Warrant Holder at his address last shown on
the records of the Company, notifying such holder of the redemption, specifying
the date of the redemption ("Redemption Date") and the date on which such
holder's exercise rights terminate (which shall be no more than 5 business days
prior to the Redemption Date) and calling upon such holder to surrender to the
Company, in the manner and at the place designated, his Warrant, to the extent
unexercised. From and after the Redemption Date, the Warrant Holder shall have
no rights with respect of the Warrant except the right to receive the Redemption
Fee without interest upon surrender of his Warrant.

Section 7. Rights As Stockholder. Prior to exercise of this Warrant, the Warrant
Holder shall have no rights as a stockholder of the Company with respect to the
Warrant Shares, including the right to vote such shares, receive dividends or
other distributions, or be notified of stockholder meetings.

Section 8. Replacement of Warrant. Upon receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of the
Warrant and, in the case of any of the foregoing, upon delivery of an indemnity
agreement or security reasonably satisfactory in form and amount to the Company
or, in the case of any such mutilation, on surrender and cancellation of such
Warrant, the Company at its expense will execute and deliver, in lieu thereof, a
new Warrant of like tenor.

Section 9. Restricted Securities. The securities evidenced by this Warrant have
not been registered under the U.S. Securities Act of 1933, as amended, or any
other laws and have been issued in reliance upon an exemption from the
registration requirements of the Securities Act and such other laws. Neither the
securities evidenced by this certificate nor any interest or participation
herein may be offered, sold, assigned, transferred, pledged, encumbered,
hypothecated or otherwise disposed of except pursuant to an effective
registration statement under the Securities Act or in a transaction exempt from,
or not subject to, the registration requirements of the Securities Act. Any
replacement Warrants issued pursuant to Sections 2 or 8 hereof and any Warrant
Shares issued upon exercise hereof, shall bear the legend set forth at the head
of this Warrant. Such legend shall only be removed in the event that the
security which would otherwise bear such legend is registered pursuant to the
Securities Act and the party seeking to remove such legend provides the Company
with an opinion of counsel, which opinion shall be satisfactory to the Company,
stating the removal of such legend is appropriate.

Section 10. Registration Rights. The Company will use commercially reasonable
efforts to register the Warrant Shares on Form S-3 pursuant to the Securities
Act and to keep such registration effective for the lesser of (i) 24 months from
the date of exercise or (ii) until such time as all Warrant Shares have been
sold. The Company shall file, or amend, a Form S-3 registration statement to
effect the registration of the Warrant Shares within 30 business days from the
Closing Date and shall use commercially reasonable efforts to have such
registration statement declared effective no later than 120 days after filing
the Form S-3 ("Registration Date"). In the event the Company fails to register
the Warrant Shares by the Registration Date the Company shall pay a fee of 1.0%
of the Aggregate Exercise Price to the Warrant Holder as liquidated damages.

Section 11. Notices. All notices, demands, requests, consents, approvals, and
other communications required or permitted hereunder shall be in writing and
shall be deemed duly given upon receipt, on the fifth business day thereafter if
deposited in the mail or upon confirmation of transmission if transmitted by
electronic means. The addresses and facsimile numbers for such communications
shall be:

if to the Company:     Immtech International, Inc.
                       150 Fairway Drive
                       Suite 150
                       Vernon Hills, IL 60061
                       Attention:  T. Stephen Thompson, Chief Executive Officer
                       Telephone:  (847) 573-0033
                       Facsimile:  (847) 573-8288

if to Warrant Holder:

                       Telephone:
                       Facsimile:

      Either party hereto may from time to time change its address or facsimile
number for notices under this Section 11 by giving written notice of such change
to the other party hereto.

Section 12. Miscellaneous.

      (a) Headings. The headings in this Warrant are for purposes of reference
only, and shall not limit or otherwise affect any of the terms hereof.

      (b) Applicable Law. This Warrant shall be governed by the internal laws of
the State of New York, without giving effect to the conflicts of law provisions
thereof.

      (c) Severability. The invalidity or unenforceability of any provision
hereof shall in no way affect the validity or enforceability of any other
provision.

      (d) Entire Agreement. This Warrant constitutes the entire agreement among
the parties with respect to the subject matter hereof. No amendment to this
Warrant shall be effective unless in writing signed by the party against which
enforcement of such is sought.

      (e) Dispute Resolution. If the parties hereto are unable to resolve any
dispute under this Warrant by negotiations, the dispute shall be exclusively
settled by confidential arbitration under the then current Commercial
Arbitration Rules of the American Arbitration Association in New York City by
three arbitrators, one selected by the Company, one by the Warrant Holder and
the third by the two so selected. Judgment upon any arbitrators' award may be
entered in any court having jurisdiction. The arbitrators shall have no
authority to amend this Warrant.

      IN WITNESS WHEREOF, this Warrant was duly executed by the undersigned,
thereunto duly authorized, as of the date first set forth above.

                              IMMTECH INTERNATIONAL, INC.

                              By: ____________________________________________
                                  Name:  T. Stephen Thompson
                                  Title: President and Chief Executive Officer

Attested:

By: _________________________________________
    Name:  Gary Parks
    Title: Treasurer, Secretary and Chief Financial Officer
<PAGE>

                              WARRANT EXERCISE FORM
                           IMMTECH INTERNATIONAL, INC.

      The undersigned ("Warrant Holder") hereby irrevocably exercises the right
to purchase __________________ shares of Common Stock, $0.01 par value, of
Immtech International, Inc., an entity organized and existing under the laws of
the State of Delaware (the "Company"), evidenced by the attached Warrant, and
herewith makes payment of the Aggregate Exercise Price for such shares in full
in the form of (check the appropriate box) (i) by certified or bank check in the
amount of $________ per Share and the aggregate amount of $___________ or (ii)
by wire transfer of immediately available funds to an account designated by the
Company.

      By delivering this notice, the undersigned agrees to be subject to the
terms and conditions of the attached Warrant.

      The undersigned requests that stock certificate(s) for the Shares to be
issued pursuant to this Warrant Exercise Form, and any Warrant representing any
unexercised portion hereof be issued, in the name of the Warrant Holder and
delivered to the undersigned at the address set forth below and be registered on
the books and records of the Company with the transfer agent.

Dated:_________________________________

_______________________________________
Signature of Warrant Holder

_______________________________________
Name of Warrant Holder (Print)

_______________________________________
Address

                                     NOTICE

      The signature to the foregoing Exercise Form must correspond to the name
as written upon the face of the attached Warrant in every particular, without
alteration, enlargement or any other change whatsoever.EXHIBIT 10.1

================================================================================

[ ** ] = This mark indicates portions of the text which have been omitted and
filed separately with the Securities and Exchange Commission pursuant to a
request for confidential treatment of such omitted text in accordance with Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

                                LICENSE AGREEMENT

                          DATED AS OF JANUARY 28, 2002

                                      AMONG

                 THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

                                AUBURN UNIVERSITY

                                 DUKE UNIVERSITY

               GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

                                       AND

                           IMMTECH INTERNATIONAL, INC.

================================================================================

<PAGE>

                                LICENSE AGREEMENT

      THIS LICENSE AGREEMENT is made and entered into as of January 28, 2002
(the "Effective Date"), among THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
(hereinafter referred to as "UNC"), AUBURN UNIVERSITY, DUKE UNIVERSITY, GEORGIA
STATE UNIVERSITY RESEARCH FOUNDATION, INC. (hereinafter all of the foregoing
entities, including UNC, shall be collectively referred to as the "Licensors"),
and IMMTECH INTERNATIONAL, INC., a corporation organized and existing under the
laws of the State of Delaware (hereinafter referred to as "Licensee").

                               W I T N E S S E T H

      WHEREAS, as anticipated by that certain Formation of Research
Collaboration Letter Agreement effective January 15, 1997, as amended by (a)
that certain Amendment to Letter Agreement effective as of October 15, 1997, (b)
that certain Second Amendment to Letter Agreement effective as of January 15,
1998, and executed in May, 1998 (the "Second Amendment"), (c) that certain Third
Amendment to Letter Agreement effective as of October 1, 1998, and executed in
January, 1999 (the "Third Amendment"), (d) that certain Fourth Amendment to
Letter Agreement effective as of October 1, 1998, and executed in March, 1999,
(e) that certain Addendum to Fourth Amendment to Letter Agreement executed in
April, 1999, and (f) that certain Second Addendum to Fourth Amendment to Letter
Agreement executed in April, 1999 (collectively with all such amendments and
addenda, the "1997 Letter Agreement"), between UNC on behalf of the Licensors,
Licensee and Pharm-Eco Laboratories, Inc. ("Pharm-Eco"), Licensee completed its
initial public offering (the "IPO"), which became effective on or about April
28, 1999.

      WHEREAS, it was anticipated in the 1997 Letter Agreement that upon
completion of its IPO, Licensee and the Licensors would enter into an agreement
with respect to the licensing of the Future Compounds (as defined below).

      WHEREAS, each of the Licensors has, by separate agreement, authorized UNC
to negotiate this Agreement on their behalf, and by the signature of their
authorized representatives below, hereby consent to UNC's assuming, on the
Licensors' behalf, certain duties and responsibilities as set forth herein.

         NOW, THEREFORE, for and in consideration of the covenants, conditions,
and undertakings hereinafter set forth, it is agreed by and between the parties
as follows:

1. DEFINITIONS

     1.1 "Affiliate" means, with respect to any particular Person, any other
Person which controls, is controlled by, or is under common control with such
particular Person. A Person shall be regarded as in control of another Person if
the first Person owns or controls, directly or indirectly, at least fifty
percent (50%) of the voting stock (or other voting equity) of the second Person.
In the case of a Non-Profit Entity, control will be deemed to exist if any
Person possesses, directly or indirectly, the power to direct or cause the
direction of the management and policies of such Non-Profit Entity.

                                      -1-

<PAGE>

      1.2 "Current Compounds" means all technology and compounds owned by one or
more of the Licensors and either licensed or optioned to Pharm-Eco as of the
date of the 1997 Letter Agreement or set forth on Exhibit A to the 1997 Letter
Agreement.

      1.3 "Future Compounds" means [ ** ].

      1.4 "Governmental Funding" means (a) that certain National Cooperative
Drug Development Grant awarded to the Licensors and Pharm-Eco during the period
from 1993 to 1997, and (b) any Small Business Innovation Research grant or Small
Business Technology Transfer ("STTR") grant which was or is applied for jointly
by Licensee and any one or more of the Licensors.

      1.5 "Licensed Field" means, and is limited to, the practice of the Future
Compounds (and the Current Compounds, if covered under this Agreement pursuant
to Section 26.1) for all fields of use.

      1.6 "Licensed Products" means any method, procedure, product, or component
part thereof whose manufacture, use or sale includes any use of University
Technology or is covered by one or more valid and unexpired claims of the Patent
Rights.

      1.7 "Licensed Territory" means the entire world.

      1.8 "Net Sales" means the total Net Sales Price of Licensed Products sold
by Licensee and its Affiliates, after deducting actual allowances for returned
or defective goods, less discounts. Licensed Products will be considered sold
when billed out, when delivered, or when paid for before delivery, whichever
first occurs. Net Sales shall not include sales for pre-clinical or clinical
trial purposes.

      1.9 "Net Sales Price" means the actual sales receipts, less any charges
for (a) sales taxes, tariffs, duties or other taxes separately stated on the
invoice, and (b) shipping and insurance charges.

      1.10 "Non-Profit Entity" means (a) any entity, agency or organization that
is not an Affiliate of Licensee and that purchases any Licensed Product in bulk
for distribution or use in developing countries, or (b) any non-profit or
charitable entity, agency or organization that is not an Affiliate of Licensee.
Developing countries shall include countries which have a Per Capita GDP less
than the Per Capita GDP Threshold.

      1.11 "Patent Rights" means the rights of any Licensor in (a) any U.S.
patents and/or patent applications which cover, or relate to, the Future
Compounds, and/or their use or manufacture, and which are owned, exclusively
licensed, or otherwise controlled by the Licensors, and which patents and/or
patent applications were filed prior to or are filed during the term of this
Agreement, (i) for which such Licensor has the right to grant a license
hereunder,

--------
 **      Confidential Treatment Requested.

                                      -2-

<PAGE>

and (ii) for which the inventions claimed therein were made in the
performance of research funded through the use of (A) Licensee-sponsored
research funding under a sponsored research agreement, (B) Governmental Funding
made available to any of the Licensors, or (C) funds expended by Licensee or
obtained through Licensee's efforts or assistance, including, without
limitation, all of the funds provided (and to be provided) by the Gates Grant
and by any other charitable or non-profit organization which funds a program in
which both Licensee and any Licensor are participants, and (b) any
continuations, continuations in part, divisionals, provisionals, continued
prosecution applications, or reissues thereof, any PCT application corresponding
to any of the foregoing, and any patents and patent applications (or their
functional equivalents) in foreign countries corresponding to any of the
foregoing, in each case subject to the statutory rights of the United States
Government in inventions which were made in the performance of research which it
funded. As of the Effective Date, the patents and patent applications included
in the Patent Rights are set forth in Exhibit A attached hereto.

      1.12 "Per Capita GDP" means, for any particular country, the per capita
gross domestic product of such country, as determined by the Statistics Division
of the United Nations Secretariat and International Labour Office (or any
successor thereto), for the most recent year for which such data is then
available.

      1.13 "Per Capita GDP Threshold" means, for any particular country, the
amount of $10,000; provided, however, that, for each year after 1998 for which
both the per capita gross domestic product for such country and the annual
inflation rate for such country (in each case as determined by the Statistics
Division of the United Nations Secretariat and International Labour Office (or
any successor thereto)) is then available, such threshold amount shall be
increased by the annual inflation rate for such country for each such year after
1998, such that such threshold amount is compounded on an annual basis by the
annual inflation rate for such country.

      1.14 "Person" means any natural person or any corporation, company,
partnership, limited liability company, trust, estate, association,
unincorporated association, governmental authority, custodian, nominee, or any
other individual entity or organization in its own or any representative
capacity, or other entity.

      1.15 "University Technology" means any published or unpublished research
and development information, know-how, and technical data (but excluding any
Patent Rights) which is in the possession of any of the Licensors or their
respective employees on or after the Effective Date, or which is developed by
any Licensor during the term of this Agreement, (a) for which any Licensor has
the right to grant a license hereunder, (b) which is necessary for the practice,
use or further development of the Future Compounds, and (c) which resulted,
results, was developed, or is developed through the use of (i)
Licensee-sponsored research funding under a sponsored research agreement, (ii)
Governmental Funding made available to any of the Licensors, or (iii) funds
expended by Licensee or obtained through Licensee's efforts or assistance,
including, without limitation, all of the funds provided (and to be provided) by
the Gates Grant and by any other charitable or non-profit organization which
funds a program in which both Licensee and any Licensor are participants.

      1.16 "Force Majeure" means prevention or delay in the performance of a
party's obligations under this Agreement if such prevention or delay is by any
cause beyond such party's

                                      -3-
<PAGE>

control, including, but not limited to, acts of God, fire, explosion, disease,
weather, war, insurrection, civil strife, riots, government action, or power
failure. Performance shall be excused only to the extent of and during the
reasonable continuance of such disability.

2. GRANT OF LICENSES AND TERM

      2.1 The Licensors hereby grant to Licensee and to Licensee's Affiliates,
to the extent of the Licensed Territory, a non-exclusive right and license to
use University Technology in the Licensed Field and the non-exclusive right to
make, use and sell Licensed Products incorporating (or manufactured using) such
University Technology in the Licensed Field, subject to all the terms and
conditions of this Agreement (the "Technology License"). Licensee may, subject
to the prior written approval of UNC on behalf of the Licensors, which approval
shall not be unreasonably withheld or delayed, grant sublicenses of the
Technology License and its rights under this Section 2.1. Sublicensees of
Licensee may not, unless permitted by the terms of the sublicense agreement,
further sublicense the rights granted to it in such sublicense agreement without
the approval of UNC (on behalf of the Licensors), which approval may not be
unreasonably withheld or delayed.

      2.2 The Licensors hereby grant to Licensee and to Licensee's Affiliates,
to the extent of the Licensed Territory, the exclusive license under and to the
Patent Rights and the exclusive right to make, use and sell Licensed Products
incorporating (or manufactured using) such Patent Rights (and not including any
University Technology) in the Licensed Field, upon the terms and conditions set
forth in this Agreement (the "Patent License", and collectively with the
Technology License, the "Licenses"). Licensee may, subject to the prior written
approval of UNC on behalf of the Licensors, which approval shall not be
unreasonably withheld or delayed, grant sublicenses of the Patent License and
its rights under this Section 2.2. Sublicensees of Licensee may not, unless
permitted by the terms of the sublicense agreement, further sublicense the
rights granted to it in such sublicense agreement without the approval of UNC
(on behalf of the Licensors), which approval may not be unreasonably withheld or
delayed.

      2.3 Each of the Licenses granted herein is for a term beginning on the
Effective Date and, unless terminated sooner as provided in this Agreement,
ending at the expiration of the last to expire patent included in the Patent
Rights.

      2.4 Licensee shall not disclose any item of unpublished University
Technology furnished by the Licensors to Licensee pursuant to Section 2.1 above
to third parties during the five (5) year period commencing on the date that
such item of unpublished University Technology is first furnished to Licensee,
provided, however, that disclosure may be made of any such item of University
Technology at any time: (a) with the prior written consent of UNC (on behalf of
the Licensors), which shall not be unreasonably withheld or delayed, or (b)
after such item shall have become public through no fault of Licensee, or (c) if
such item was known by Licensee at the time of the disclosure, as shown by
documents in existence at such time, or (d) to the Securities and Exchange
Commission, the NASD, NASDAQ, the Food and Drug Administration, and any other
U.S. or foreign governmental or regulatory agency or authority to which such
disclosure is necessary or advisable, in which case, if such disclosure is
advisable but not necessary, then Licensee shall (1) obtain the consent of UNC
on behalf of the Licensors, which consent shall not be unreasonably withheld or
delayed, and (2) to the extent practicable,

                                      -4-
<PAGE>

request confidential treatment of such disclosed University Technology by the
receiving agency or authority, or (e) to any sublicensees who have agreed to
terms no less restrictive than those in this Section, or (f) if required by law,
a court of competent jurisdiction, or any governmental or regulatory agency or
authority.

      2.5 The Licensors each represent and warrant to Licensee, as of the date
they execute and deliver this Agreement, that (a) they have the authority,
right, and power to grant to Licensee the Licenses (and the rights thereunder)
under this Agreement, (b) to the best of their knowledge, after reasonable
inquiry, there are no agreements, statutes, rules or regulations prohibiting,
restricting, or modifying such grant or limiting the Patent Rights or University
Technology covered by such Licenses, and (c) to the best of their knowledge,
after reasonable inquiry, they have not granted, sold or otherwise transferred
to any Person any licenses or other rights to any of the Patent Rights or
University Technology or Future Compounds which might reasonably be expected to
conflict with or limit the rights and Licenses granted to Licensee under this
Agreement. Notwithstanding the foregoing, any and all Licenses granted hereunder
are subject to the statutory rights of the United States Government which arise
out of its sponsorship of the research which led to the discovery or development
of Future Compounds licensed herein. Notwithstanding anything else contained in
this Agreement, each of the Licensors shall, during the term of this Agreement,
use its best efforts not to sell, grant, license, sublicense, or otherwise
transfer to any third party any rights to any Future Compounds or Patent Rights
(or to any University Technology on an exclusive basis) (or to anything that
would be a Future Compound, Patent Right or item of University Technology but
for such sale, grant, license, sublicense, or other transfer) which might
impair, limit or conflict with the rights granted to Licensee pursuant to the
Licenses (or which would have been granted to Licensee but for such sale, grant,
license, sublicense, or other transfer) and the other provisions of this
Agreement. If any Licensor becomes aware that it has entered into any
transaction described in the preceding sentence, then it shall promptly notify
Licensee of such transaction and state the other party to and the principal
terms of such transaction, and it shall take all reasonable efforts to negotiate
an agreement with such third party to reduce as much as practicable the
impairment, limitation or conflict with the rights granted to Licensee (or which
would have been granted to Licensee but for such transaction) under this
Agreement which such transaction has created. Licensee shall, shortly after the
execution and delivery of this Agreement, prepare a "plain English" summary of
each Licensor's obligations under this Agreement and provide each Licensor with
a copy of such summary. Each Licensor shall, within fifteen (15) days of its
receipt of such summary, distribute such summary to its scientists, professors,
appropriate students, employees, and other relevant persons, in an effort to
prevent any actions by any of such persons which might impair any of Licensee's
rights under this Agreement, as well as a copy to Licensee. The final decision
regarding the content of each summary shall be decided solely by the Licensor
receiving the summary.

      2.6 Any sublicenses granted pursuant to this Article 2 shall be in
accordance with the terms and conditions of this Agreement. Licensee shall
provide UNC (on behalf of the Licensors) with a copy of all sublicense
agreements within thirty (30) days of the full execution and delivery by the
sublicensee of such sublicense agreement to Licensee. Licensee shall use
commercially reasonable efforts (which efforts may include bringing suit against
a sublicensee if economically justifiable) to enforce its rights under each
sublicense agreement. Upon the termination or expiration of this Agreement,
Licensee shall assign to the Licensors each sublicense agreement, as
contemplated by Section 5.4.

                                      -5-
<PAGE>

      2.7 UNC shall provide to Licensee, as of June 30 and December 31 of each
year, within thirty (30) days of such dates, a revised Exhibit A to this
Agreement which shall have added to it all new Patent Rights to any Future
Compounds which were developed or obtained during each such six (6) month
period. If Licensee believes that any information on such revised Exhibit A is
incorrect, then Licensee and UNC (on behalf of the Licensors) shall cooperate in
good faith to address such belief to the reasonable satisfaction of the parties.
Each revised Exhibit A shall be accompanied by a statement of an authorized
signatory of each Licensor who has obtained any of such new Patent Rights that,
to the best of their knowledge, after reasonable inquiry, they have not granted,
sold or otherwise transferred to any Person any licenses or other rights to any
of the new Patent Rights, or to any University Technology related thereto, which
might reasonably be expected to conflict with or limit the rights and Licenses
granted to Licensee (or which would have been granted to Licensee but for such
grant, sale, or other transfer) under this Agreement.

      2.8 The Licenses granted to Licensee in this Agreement shall not be
construed to confer any rights upon Licensee by implication, estoppel, or
otherwise as to any technology or intellectual property owned solely or jointly
by one or more Licensors which are not included in or part of the Patent Rights
or University Technology.

3. LICENSE FEE AND ROYALTIES

      3.1 Licensee will pay to UNC on behalf of the Licensors a license fee in
the form of reimbursement of the costs (including attorney's fees) arising out
of the patenting of the Future Compounds pursuant to and in accordance with
Article 9 of this Agreement. The reimbursement of patenting costs shall be
non-refundable and shall not be a credit against any other amounts due
hereunder. Reimbursement of patenting costs shall be due upon monthly billings
from UNC containing invoices of such patenting costs with reasonable supporting
documentation.

      3.2 (a) Beginning on the Effective Date and continuing for the term of
this Agreement, Licensee will pay the Licensors, collectively as a group, and
payable through UNC, an aggregate running royalty (the "Royalty") of [ ** ].

      (b) With respect to any Future Duke Licensed Products, and solely to the
extent required by applicable federal laws and regulations, Licensee and UNC (or
Duke University), understanding that certain tax ramifications exist in regard
to royalty rates, agree to negotiate in good faith all Royalty rates for sales [
** ] of all Future Duke Licensed Products on an annual basis (as of the end of
Licensee's fiscal year) for all of the Future Duke Licensed Products which are
to be based on Future Compounds invented by Duke University which have become,
during such twelve (12) month period, subject to the Licenses granted to
Licensee under this Agreement for Future Compounds, [ ** ]. Licensee understands
and acknowledges that, if such Royalty is negotiated by UNC, then any such
Royalty rate shall be subject to Duke University's approval, which shall not be
unreasonably withheld or delayed. In the event that Licensee and UNC (or
--------
 **      Confidential Treatment Requested.

                                      -6-
<PAGE>

Duke University) fail to reach mutually acceptable terms within ninety (90) days
after commencement of negotiations with respect to the Royalty rates to be paid
to UNC on behalf of Duke University for any such Future Duke Licensed Product
(the "Negotiation Period"), then, unless Duke University submits the matter to
arbitration in accordance with Section 28.1 of this Agreement, the Royalty for
such Future Duke Licensed Products shall be the same as the Royalty on Licensed
Products which are not Future Duke Licensed Products.

      (c) [ ** ].

      (d) [ ** ].

      (e) Licensee shall use, and shall instruct its Affiliates to use,
commercially reasonable efforts to collect the payments that Licensee or its
Affiliates are owed for sales of Licensed Products.

      3.3 (a) Licensee shall make semi-annual written reports to UNC during the
life of this Agreement (the "Summary Reports"), with each Summary Report
covering one-half of Licensee's fiscal year and stating the number, description,
and aggregate Net Sales of Licensed Products sold or otherwise disposed of
during the reporting period and upon which any Royalty is payable as provided in
Section 3.2 hereof, and the amount of any such Royalty which is due. The first
Summary Report shall include all such Licensed Products, if any, so sold or
otherwise disposed of prior to the date of such report. The Summary Report for
the first half of Licensee's fiscal year shall be due [ ** ] after the end of
the first half, and shall contain an estimate of the information required to be
set forth therein. The Summary Report for the second half of Licensee's fiscal
year shall be due [ ** ] after the end of Licensee's fiscal year, and shall
contain actual amounts for both the first half and the second half of such
fiscal year. Each Summary Report may include any adjustments that may be
necessary for any prior reporting period, including, for example, adjustments
for returns or defective goods.

      (b) Until Licensee has achieved a first commercial sale of a Licensed
Product, a report shall be submitted by Licensee to UNC by the due dates set
forth in Section 3.3(a) above (a "Status Report") which will include a full
written report describing Licensee's technical and other efforts made towards
such first commercial sale for all Licensed Products then under development.

      3.4 [ ** ].

      3.5 In the event of default in payment of any payment owing to the
Licensors under the terms of this Agreement, and if it becomes necessary for the
Licensors to undertake legal action to collect said payment, then Licensee shall
reimburse the Licensors for all reasonable legal fees and costs actually
incurred by the Licensors in connection therewith; provided, however, that if
any matter involving any payment due or alleged to be due is submitted to
arbitration in accordance with Section 28.1, then such legal fees and costs
shall be allocated as the arbitration tribunal shall determine.
--------
 **      Confidential Treatment Requested.

                                      -7-

<PAGE>

      3.6 (a) [ ** ].

      (b) With respect to Future Compounds invented by Duke University
subsequent to the Effective Date or Future Duke Licensed Products, and solely to
the extent required by applicable federal laws and regulations, Licensee and UNC
(on behalf of Duke University) will negotiate in good faith for [ ** ].

      3.7 (a) [ ** ].

      (b) With respect to Future Duke Licensed Products, and solely to the
extent required by applicable federal laws and regulations, Licensee and UNC
will negotiate in good faith for [ ** ].

      3.8 UNC shall be responsible for distributing to the other Licensors any
share to which they are entitled of payments made by Licensee to UNC under this
Agreement.

      3.9 If in any fiscal year of Licensee during the term of this Agreement
after Licensee has received approval from the appropriate regulatory authority
of a New Drug Application (or its equivalent elsewhere in the Licensed
Territory), the total amounts paid or payable to UNC (for the benefit of the
Licensors) under Sections 3.2 and 3.7 combined are less than [ ** ], then
Licensee shall pay to UNC (for the benefit of the Licensors) such amount that,
when combined with the amounts paid or payable by Licensee under Sections 3.2
and 3.7, shall total [ ** ].

      3.10 [ ** ].

4. COMMERCIALIZATION EFFORTS

      4.1 Licensee shall use its commercially reasonable efforts to proceed
diligently with the manufacture and sale of Licensed Products and shall
earnestly and diligently work to obtain regulatory approval to sell Licensed
Products and to offer and continue to offer for sale such Licensed Products
after obtaining such approvals, both under reasonable conditions, during the
term of this Agreement.

      4.2 (a) Licensee shall use commercially reasonable efforts to meet a
schedule of performance milestones for each lead Future Compound. The completion
dates of each milestone with respect to any particular lead Future Compound
shall count from the date on which such lead Future Compound is selected for
clinical development by mutual agreement of Licensee and the Licensors, such
agreement not to be unreasonably delayed or withheld by any party. The schedule
of milestones for each lead Future Compound is as follows:

                          Milestone#                            Deadline
                          ----------                            --------
                                                       (Years After Selection of
                                                             Lead Compound)

       [ ** ]                                                    [ ** ]
       [ ** ]                                                    [ ** ]
       [ ** ]                                                    [ ** ]
       [ ** ]                                                    [ ** ]
       [ ** ]                                                    [ ** ]
       [ ** ]                                                    [ ** ]
--------
 **      Confidential Treatment Requested.

                                      -8-
<PAGE>

      # or their equivalents elsewhere in the Licensed Territory

      (b) The date of selection of the lead compound known as [ ** ] shall be
the Effective Date. With respect to the lead compound known as [ ** ] the
following milestones shall apply in lieu of the milestones set forth in Section
4.2(a):

                          Milestone#                            Deadline
                          ----------                            --------

       [ ** ]                                                    [ ** ]
       [ ** ]                                                    [ ** ]
       [ ** ]                                                    [ ** ]

      # or their equivalents elsewhere in the Licensed Territory

      (c) [ ** ].

      (d) The milestones set forth in this Section 4.2 represent Licensee's
realistic estimate of the schedule it will be able to keep in the event that
there are no unexpected technical or clinical obstacles. Adverse results at any
stage could significantly extend the periods required to meet any or all of the
milestones listed.

      4.3 If this Agreement becomes effective or terminates or expires during a
calendar year, then the Minimum Royalty payable to UNC under Section 3.9 for the
portion of such year during which this Agreement is in effect shall be
determined by multiplying the Minimum Royalty set forth in Section 3.9 for the
year in which this Agreement becomes effective, terminates or expires, by a
fraction, the numerator of which shall be the number of days during such
calendar year for which this Agreement is in effect and the denominator of which
shall be 365.

5. CANCELLATION

      5.1 It is expressly agreed that, notwithstanding the provisions of any
other Section of this Agreement, if Licensee should fail to deliver to UNC any
Royalty at the time or times that the same should be due to UNC on behalf of the
Licensors where there is not a dispute between Licensee and UNC or any other
Licensor with respect to the amount of the Royalty which is due, or if Licensee
should in any material respect violate or fail to keep or perform any material
covenant, condition, or undertaking of this Agreement on its part to be kept or
performed hereunder, and there is not then occurring any material breach of this
Agreement by any Licensor, then in such event UNC shall have the right, on
behalf of the Licensors, to [ ** ], upon
--------
 **      Confidential Treatment Requested.

                                      -9-
<PAGE>

[ ** ] prior written notice to Licensee if Licensee has failed to cure (unless
such failure is due to Force Majeure) such breach within [ ** ] of its receipt
of written notice from UNC describing such breach, or within such longer period
of time as may be reasonably necessary to cure such breach if, due to Force
Majeure or regulatory changes, such breach is not reasonably likely to be cured
within such [ ** ] period. If Licensee shall commit a material breach of this
Agreement as described in the first sentence of this Section 5.1 more than [ **
] times in any [ ** ] consecutive [ ** ], then UNC shall have the right, on
behalf of the Licensors, to [ ** ] upon [ ** ] prior written notice to Licensee,
without having to permit Licensee the opportunity to cure. If UNC does not
exercise its right [ ** ] within [ ** ] of the later of (a) the date of
discovery by any Licensor of the breach which triggered the loss of Licensee's
right to cure under the preceding sentence, or (b) the date on which the cure
for the most recent prior breach was completed, then Licensee's right to cure
shall be automatically reinstated.

      5.2 Alternatively, should Licensee be in breach or default as set forth in
Section 5.1 above, and should UNC be in a position where [ ** ] in accordance
with Section 5.1, then in its sole discretion after seeking the advice of the
other Licensors, which advice shall be given due consideration by UNC, UNC may
convert the exclusive Licenses to non-exclusive Licenses upon giving [ ** ]
notice of such decision to Licensee.

      5.3 If Licensee should be adjudged bankrupt or enter into a composition
with or assignment for the benefit of its creditors, then in such event the
Licensors shall, subject to bankruptcy law and the rulings of the bankruptcy
court, have the right to cancel and terminate this Agreement, and the Licenses
herein provided for, upon thirty (30) days prior written notice to Licensee.

      5.4 Any sublicense agreements entered into by Licensee under this
Agreement which are in effect at the time of any termination (for any reason) or
expiration of this Agreement shall continue in full force and effect and shall
be assigned by Licensee to the Licensors, effective as of the date of
termination or expiration, as the case may be, of this Agreement.

      5.5 Any termination or cancellation under any provision of this Agreement
shall not relieve Licensee of its obligation to pay (a) any Royalty or other
fees (including attorney's fees pursuant to Section 3.1 hereof) due or owing at
the time of such cancellation or termination, or (b) any payment due to the
Licensors under Section 6.1 hereof.

      5.6 Unless terminated sooner under the provisions of this Agreement, this
Agreement will continue in full force and effect until the last patent included
in the Patent Rights has expired or been finally held (by a court of competent
jurisdiction) to be invalid or unenforceable.

      5.7 Licensee may, at any time, terminate this Agreement upon twelve (12)
months written notice to UNC.

      5.8 Within thirty (30) days of the termination of this Agreement under
Sections 5.1 or 5.3, Licensee shall provide to the Licensors copies of all
market clearance applications associated with regulatory approval of Licensed
Products (including all data thereto) and all data
--------
 **      Confidential Treatment Requested.

                                      -10-
<PAGE>

related to as yet unfiled market clearance applications associated with
regulatory approval of Licensed Products. The Licensors shall promptly reimburse
Licensee for its reasonable costs and expenses in complying with this Section
5.8. Licensee shall grant to the Licensors a non-exclusive worldwide
royalty-free right and license to use all such applications and data for all
purposes.

      5.9 Upon the written request of UNC following any termination of this
Agreement under Sections 5.1 or 5.3, Licensee shall return to UNC, on behalf of
the Licensors, or destroy as directed by UNC, on behalf of the Licensors, all
information, data, and any relevant materials provided to Licensee during the
term of this Agreement which are covered by any of the Patent Rights. Licensee
shall provide UNC with a written statement signed by an authorized
representative of Licensee stating that the same has been so delivered or
destroyed, whichever is appropriate. Notwithstanding the foregoing, Licensee
shall be allowed to (a) retain one copy of such information, data and materials
provided to Licensee for purposes of documenting its obligations under this
Agreement, and (b) retain up to three (3) additional copies of such information,
data and materials in order to enable Licensee to continue with its business
operations with respect to products which are no longer covered by any Patent
Rights of the Licensors.

      5.10 Notwithstanding any other provision of this Agreement, if Licensee
does not satisfy its obligations to continue to make payments to UNC (for the
benefit of the Licensors) after the Effective Date as set forth under Section
3(d) (last sentence only, as amended) of the 1997 Agreement, then UNC may (on
behalf of the Licensors) deliver to Licensee a notice stating Licensee's failure
to satisfy such obligations. Licensee shall have thirty (30) days from its
receipt of such notice to cure such failure. If Licensee shall fail to cure such
failure within such thirty (30) day period, then UNC may (on behalf of the
Licensors) deliver a notice to Licensee stating the Licensors' election to
rescind this Agreement and the 1997 Agreement effective as of a date specified
in such notice, such date to be no earlier than ten (10) days after the date of
delivery of such election notice.

6. DISPOSITION OF LICENSED PRODUCTS ON HAND UPON CANCELLATION OR TERMINATION

      6.1 Upon cancellation or termination of this Agreement other than as
provided in Section 5.4, Licensee shall provide UNC with a written inventory of
all Licensed Products in process of manufacture, in use or in stock. Licensee
shall have the privilege of disposing of the inventory of such Licensed Products
within a period of one hundred and eighty (180) days of such termination upon
conditions most favorable to UNC that Licensee can reasonably obtain; provided,
however, that Licensee pay to UNC (for the benefit of the Licensors) a Royalty
or any other payment due thereon as calculated in accordance with Article 3.
Licensee will also have the right to complete performance of all contracts
requiring use of either University Technology, Patent Rights (except in the case
of termination pursuant to Section 5.1), Future Compounds, the Licenses, or
Licensed Products within and beyond said 180-day period; provided, however, that
Licensee pay to UNC (for the benefit of the Licensors) a Royalty or any other
payment due thereon as calculated in accordance with Article 3. If the remaining
term of any such contract exceeds one (1) year, then (a) such contract shall
continue in full force and effect, (b) the Licenses granted hereunder shall
remain in effect solely for the purpose of enabling Licensee to fulfill its
obligations under such contract, (c) Licensee shall no longer be permitted to
enter into

                                      -11-
<PAGE>

any additional contracts requiring the use of any University Technology, Patent
Rights, Future Compounds, Licenses, or Licensed Products, and (d) Licensee
shall, after such one (1) year period, forward to UNC one hundred percent (100%)
of any receipts (other than reimbursement of Licensees expenses or any
indemnification payments) that Licensee thereafter receives under such contract
for the period after such one (1) year period. All Licensed Products which are
not disposed of as provided above shall be delivered to UNC or otherwise
disposed of, in UNC's sole discretion, and at Licensee's sole expense.

7. USE OF THE NAMES OF THE LICENSORS

      7.1 The use of the name of the Licensors, or any contraction thereof, in
any manner in connection with the exercise of the Licenses is expressly
prohibited except with prior written consent of UNC (on behalf of the Licensor
whose name is requested to be used); provided, however, that no such consent
shall be required for Licensee to identify the Licensors and describe its
relationship and transactions with the Licensors in connection with (a)
communications and filings with the Securities and Exchange Commission, the
NASD, NASDAQ, the Food and Drug Administration, or other governmental or
regulatory agencies or authorities, as reasonably advisable in connection with
or required by such agencies or authorities, (b) the inclusion of the
Descriptive Statement attached hereto as Exhibit B in any communications or
other documentation relating to any financing or fund-raising by Licensee, and
(c) the preparation of Licensee's financial statements. In preparing any such
description, Licensee shall not make any claims or statements that any Licensor
has endorsed any product or product candidate of Licensee, without the prior
written consent of UNC (on behalf of such Licensor).

      7.2 Duke University may, without express prior written consent of the
other parties to this Agreement, issue an announcement of the execution of this
Agreement, containing only the names of the inventors of the Patent Rights and
the name of Licensee and the names of the other Licensors, in the Duke Dialogue
and in other internal reports and publications.

      7.3 Neither Licensee, any Affiliate or sublicensee of Licensee, nor any
Licensor (each of all of the foregoing, a "Relevant Party") shall, individually
or collectively, without the express, prior written consent of the appertaining
Relevant Party, (a) use, unless otherwise permitted in this Agreement, in either
advertising, publicity, press release, promotional activity, or other similar
activity, the name or image of (i) such appertaining Relevant Party or any of
its employees, officers, directors, students, or agents, or (ii) any
trade-names, trademarks, trade devices, service marks, symbols or any
abbreviation, contraction or simulation thereof, which is owned by such
appertaining Relevant Party, or (b) make any representations, either directly or
indirectly, about any product or service of any one or more Relevant Parties.

      7.4 If any Relevant Party desires to make any use or representation which
is restricted pursuant to Section 7.3 above, then such Relevant Party shall
request the written consent of the appertaining Relevant Party and submit to
such appertaining Relevant Party a copy of the proposed use or representation.
The appertaining Relevant Party shall use its commercially reasonable efforts to
respond to the requesting Relevant Party within ten (10) days of its receipt of
the copy of such proposed use or representation from the requesting Relevant
Party.

                                      -12-
<PAGE>

8. LICENSORS' USE

      8.1 It is expressly agreed that, notwithstanding any provisions herein,
each Licensor is free to use its University Technology, Patent Rights and
Licensed Products for its own research, public service, clinical, teaching and
educational purposes without payment of royalties; provided, however, that no
Licensor shall sell or distribute any Patent Rights or Licensed Products (or any
University Technology on an exclusive basis) for commercial use or benefit, nor
shall any Licensor donate any Licensed Products for use in any market in which
Licensee is selling such Licensed Product or any competing Licensed Product.
Furthermore, the Licensors shall be free to publish and publicly disclose at
scientific meetings University Technology, as they see fit; provided, however,
that if any such University Technology is not protected by any Patent Rights,
then any Licensor desiring to publish or disclose such University Technology
shall (a) notify Licensee in writing of its intent to so publish or disclose,
providing with such notice a copy of the proposed publication or disclosure for
Licensee's review, and (b) provide Licensee with a reasonable time period (for
which the Licensors shall use commercially reasonable efforts to provide ninety
(90) days, but which shall not be less than forty-five (45) days in any case) to
arrange for the filing, prior to any such publication or disclosure by such
Licensor, of a patent application covering such University Technology as
provided in Article 9.

9. PATENTS AND INFRINGEMENTS

      9.1 Each of the Licensors and Licensee shall each cooperate in good faith
with each other to obtain, maintain and defend any and all of the Patent Rights.
Licensee shall continue to bear the cost of filing, prosecuting, maintaining and
defending all U.S. and foreign patent applications and patents included within
the Patent Rights. Licensee shall reimburse all amounts due pursuant to this
Section 9.1 within thirty (30) days of its receipt of an invoice therefor from
UNC. Such filings and prosecutions shall be (a) in the name or names of the
Licensors employing the inventors of a particular invention, as defined under
patent law, and (b) by experienced patent counsel chosen by UNC. UNC shall keep
Licensee advised on a timely basis as to the prosecution of such applications
and shall, shortly after the execution and delivery of this Agreement, instruct
its patent counsel in writing to deliver to Licensee, on a timely basis, copies
of all correspondence and other documents (including, but not limited to,
Applications, Office Actions, responses, etc.) which are received by or sent by
such patent counsel and which relate to any Patent Right (including, without
limitation, all patents and patent applications included, or to be included,
within the Patent Rights). Licensee shall have the right to advise UNC as to
such prosecution, and further, shall have the right to make reasonable requests
as to the conduct of such prosecution. All final decisions pertaining to the
prosecution of all patents and patent applications included in the Patent Rights
shall be at the sole discretion of UNC, on behalf of the Licensors. Licensee
shall notify UNC at least ninety (90) days prior to any statutory deadlines for
responding to office actions, filing additional applications, and similar
matters, or within forty-five (45) days after receiving notice from UNC of any
deadline if the statutory deadline is ninety (90) days or less after receipt of
such notice from UNC, as to what steps it would like UNC to take. UNC shall,
shortly after the execution and delivery of this Agreement, instruct its patent
counsel in writing that in the event of any dispute between Licensee and either
UNC or any other of the Licensors with respect to any patent, patent application
or other Patent Right, such counsel shall deliver to Licensee, on a timely
basis, upon written request from Licensee, and at Licensee's expense, a copy of
any documents requested by Licensee which are relevant to the patent matter
which is the subject of such dispute, excluding, however, any documents
protected by the attorney-client privilege.

                                      -13-
<PAGE>

      9.2 As regards foreign patent applications corresponding to the U.S.
patent applications described in Section 9.1 above, Licensee shall designate at
least ninety (90) days prior to any statutory deadline that country or those
countries, if any, in which Licensee desires such corresponding patent
application(s) to be filed. Licensee shall pay all costs and legal fees
associated with the preparation, filing, prosecution and maintenance of such
designated foreign patent applications and such applications shall be in the
name or names of the Licensors employing the inventors of a particular
invention, as defined under patent law. The Licensors may elect to file
corresponding patent applications in countries other than those designated by
Licensee. If the Licensors elect to do so and Licensee does not agree, within
thirty (30) days of receiving notice from UNC of such election by the Licensors,
to pay all costs and legal fees associated with the filing of such corresponding
patent applications in the non-designated countries, then the individual
Licensors exercising such right shall be responsible for all costs and legal
fees associated with the filing of such corresponding patent applications in
such non-designated countries. In such event, Licensee shall forfeit its rights
under the Licenses to the Patent Rights associated with such corresponding
patent applications in the non-designated country(ies) where the Licensors
exercise their option to file such corresponding patent applications.

      9.3 If the production, sale or use of Licensed Products under this
Agreement by Licensee results in any claim for patent infringement against
Licensee, then Licensee shall promptly notify UNC thereof in writing, setting
forth the facts of such claim in reasonable detail. As between the parties to
this Agreement, Licensee shall have the first and primary right and
responsibility at its own expense to defend and control the defense of any such
claim against Licensee, by counsel of its own choice. [ ** ]. The Licensors
agree to cooperate with Licensee in any reasonable manner (including, without
limitation, providing evidence and witnesses (including the inventors) within
their control) which may reasonably be expected to be necessary or advisable in
defending against any such action or negotiating any settlement of such action.
Licensee shall reimburse the Licensors for any reasonable and actual
out-of-pocket expenses incurred in providing such assistance; provided, however,
that reimbursement of any expense of $2,500 or more shall require the submission
to Licensee of third-party invoices for such expenses.

      9.4 In the event that any Patent Rights licensed to Licensee are infringed
by a third party, Licensee shall have the primary right, but not the obligation,
to institute, prosecute and control any action or proceeding with respect to
such infringement, by counsel of its choice, including any declaratory judgment
action arising from such infringement, and Licensee shall bear all expenses for
such action or proceeding and shall be entitled to the entire amount of any
settlement or judgement paid by the third party; provided, however, that if any
part of any settlement or judgement is stated to be compensation to Licensee for
lost sales of a Licensed Product, then Licensee shall pay to UNC on behalf of
the Licensors the appropriate Royalty on such part of the settlement or
judgement. The Licensors agree to cooperate with Licensee in any
--------
 **      Confidential Treatment Requested.

                                      -14-
<PAGE>

reasonable manner which may reasonably be expected to be necessary or advisable
in connection with any such action or proceeding, including, without limitation,
allowing Licensee to institute and maintain the action or proceeding in the name
of the Licensor(s) who owns the patent(s) which are infringed, providing
evidence and witnesses (including the inventors) within its control, performing
such other acts as Licensee may reasonably request, and executing, verifying,
and delivering such documents as are needed or as Licensee may reasonably
request. Licensee shall reimburse the Licensors for any and all commercially
reasonable out-of-pocket expenses incurred in providing such assistance upon
submission to Licensee of third-party invoices for such expenses.

      9.5 Notwithstanding the foregoing, and in the Licensors' sole discretion,
the Licensors who own the Patent Rights that are the subject of a legal action
involving the Future Compounds shall be entitled to participate in such action
through counsel of their own choosing. Nothing in the foregoing sections shall
be construed in any way which would limit the authority of the Attorney General
of North Carolina.

      9.6 All Licensed Products (and/or their containers, labels, and/or other
packaging) sold in the United States shall be marked with all applicable United
States patent numbers. All Licensed Products (and/or their containers, labels,
and/or other packaging) shipped to or sold in other countries shall be marked in
such a manner as to conform with the patent laws and practice of the country of
manufacture or sale.

10. WAIVER

      10.1 It is agreed that no waiver by any party hereto of any breach or
default of any of the covenants or agreements herein set forth shall be deemed a
waiver as to any subsequent and/or similar breach or default. Any and all
waivers must be expressly stated in writing signed by the party granting any
such waiver.

11. LICENSE RESTRICTIONS

      11.1 It is agreed that the rights and privileges granted to Licensee are
each and all expressly conditioned upon the faithful performance on the part of
the Licensee of every requirement herein contained, and that each of such
conditions and requirements may be and the same are specific License
restrictions.

12. ASSIGNMENTS

      12.1 This Agreement is binding upon and shall inure to the benefit of the
Licensors, their successors and assigns. However, this Agreement shall be
personal to Licensee and it is not assignable by Licensee to any other entity
without the express prior written consent of UNC, which consent shall not be
withheld or delayed unreasonably; provided, however, that Licensee may, without
such consent, assign this Agreement to (a) any of its Affiliates, and (b) any
Person acquiring all or substantially all of Licensee's assets.

                                      -15-
<PAGE>

13. INDEMNITY

      13.1 Licensee agrees to indemnify, hold harmless and defend the Licensors,
their trustees, officers, employees, students, and agents, against any and all
claims, suits, losses, damage, costs, fees, and expenses asserted by third
parties, both government and private, resulting from or arising out of the
exercise of the Licenses by Licensee, except to the extent that any such claim,
suit, loss, damage, cost, fee, or expense is attributable to any negligence or
intentional misconduct of any Licensor, any inventor, or any trustee, officer,
employee, student or agent of any Licensor or any inventor.

14. INSURANCE

      14.1 Licensee shall maintain in force at its sole cost and expense, with
reputable insurance companies, general liability insurance and products
liability insurance coverage in an amount reasonably sufficient to protect
against liability under Section 13.1, above. UNC shall have the right to request
copies of customary policy documents which evidence such coverage, in order to
ascertain from time to time that such coverage exists, such right to be
exercised in a reasonable manner.

15. INDEPENDENT CONTRACTOR STATUS

      15.1 No party hereto is an agent of the other for any purpose except as
expressly set forth in (a) this Agreement, (b) the Patent Plan executed by the
Licensors on July 26, 1994, and (c) the Inter-Institutional Agreement dated
January 15, 1997, among the Licensors.

16. LATE PAYMENTS

     16.1 In the event Royalty payments or fees are not received by UNC when
due, and there is not a dispute between Licensee and UNC or any other Licensor
with respect to the amount of the Royalty which is due, then Licensee shall pay
to UNC interest at an annual rate (the "Late Rate") equal to the prime rate (as
quoted in the Wall Street Journal) plus two percent (2%) on the amount of
Royalties or fees which are past due. The payment of such interest shall not
foreclose the Licensors from exercising any other rights they may have under
this Agreement as a consequence of the lateness of any payment.

17. WARRANTIES

      17.1 The Licensors make no warranties that any patent will be issued on
University Technology or Future Compounds. To the best knowledge of each of the
Licensors, the patents comprising the Patent Rights held by such Licensor are
valid and enforceable. The Licensors further make no warranties, express or
implied, as to any matter whatsoever, including, without limitation, the
condition of any invention(s) or product(s), that are the subject of this
Agreement; or the merchantability or fitness for a particular purpose of any
such invention or product. The Licensors shall not be liable for any direct,
consequential, or other damages suffered by Licensee resulting from the use of
the Future Compounds or Licensed Products, except (a) to the extent that any
such damage is attributable to any patent infringement, negligence or
intentional misconduct of any Licensor, any inventor, or any officer, employee,
student or agent of any Licensor or any inventor, and (b) to the extent that
such Licensor may be held liable for such infringing, negligent or intentional
act.

                                      -16-
<PAGE>

     17.2 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER THE
LICENSORS, NOR THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES,
STUDENTS AND/OR AFFILIATES MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES OF
ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS
CLAIMS, ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER
OR NOT DISCOVERABLE. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
REPRESENTATION MADE OR WARRANTY GIVEN BY THE LICENSORS THAT THE PRACTICE BY
LICENSEE, ITS AFFILIATES, AND/OR SUBLICENSEES OF THE LICENSES GRANTED HEREUNDER
SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL THE
LICENSORS, OR THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES,
STUDENTS AND/OR AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF
ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS,
REGARDLESS OF WHETHER THE LICENSORS SHALL BE ADVISED, SHALL HAVE OTHER REASON TO
KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF SUCH DAMAGES.

18. ACCOUNTING AND RECORDS

      18.1 Licensee will keep complete, true and accurate books of account and
records for the purpose of showing the derivation of all amounts payable to the
Licensors through UNC under this Agreement. Such books and records will be kept
at Licensee's principal place of business for at least three (3) years following
the end of the calendar quarter to which they pertain, and will be open at all
reasonable times during normal business hours for inspection by a representative
of UNC for the purpose of verifying Licensee's Royalty statements, or Licensee's
compliance in other respects with this Agreement. The representative will be
obliged to treat as confidential all relevant matters and shall, if requested by
Licensee, execute an appropriate confidentiality and non-disclosure agreement.

      18.2 Such inspections shall be at the expense of the Licensors, unless a
variation or error resulting in an underpayment of Royalties of at least the
greater of (a) U.S. $10,000, or the equivalent in foreign currency, or (b) one
point five percent (1.5%) of the total amount of Royalties due for the period
during which the variation or error was in effect, is discovered in the course
of any such inspection, whereupon all costs relating thereto shall be paid by
Licensee.

      18.3 Licensee will promptly pay to UNC the full amount of any Royalty
underpayment, together with interest thereon at the Late Rate; provided,
however, that such Royalty underpayment is not subject to a dispute between
Licensee and UNC or any other Licensor with respect to the amount of the Royalty
which is due.

                                      -17-
<PAGE>

19. COMPLIANCE WITH LAWS

      19.1 In exercising its rights under the Licenses, Licensee shall fully
comply with the requirements of any and all applicable laws, regulations, rules
and orders of any governmental body having jurisdiction over the exercise of
rights under the Licenses. Licensee further agrees to indemnify and hold the
Licensors and their respective trustees, officers, employees and agents harmless
from and against any costs, expenses, attorney's fees, citations, fines,
penalties and liabilities of every kind and nature which are imposed by reason
of any established violation of any such laws, order, rules and/or regulations,
except to the extent that any of such violation or any of such costs, expenses,
attorney's fees, citations, fines, penalties or liabilities is attributable to
the negligence or intentional misconduct of any Licensor, any inventor, or any
trustee, officer, employee, student or agent of any Licensor or inventor.

20. U.S. MANUFACTURE

      20.1 The parties hereto agree that any Licensed Products sold in the
United States shall be substantially manufactured in the United States.

21. NOTICES

      21.1 Any payment or notice required or permitted to be given to the
parties hereto shall be deemed to have been properly given if (a) delivered in
person, (b) delivered by a reputable overnight delivery service which records
the name of the individual accepting delivery (such as, for example, FedEx, DHL,
Airborne Express, UPS, or USPS Express or Priority Mail), (c) mailed by
first-class certified or registered mail, return receipt requested, or (d)
delivered by successful telecopier transmission, with a hard copy of such
transmission delivered in the manner specified in the preceding clauses (a), (b)
or (c), in each case to the other party or parties at the appropriate address or
telecopier number as set forth below or to such other addresses or telecopier
numbers as may be designated by notice to each of the other parties hereto from
time to time during the term of this Agreement. Notices shall be deemed received
on the date on which they are actually delivered to the recipient (in the case
of telecopier transmission, the date of delivery shall be the date of
transmission, if transmitted prior to 5:30 P.M. in the time zone of the
recipient, else the next business day after transmission).

                  If to any of the Licensors, to:

                           The University of North Carolina at Chapel Hill
                           Office of Technology Development
                           CB #4105, 308 Bynum Hall
                           Chapel Hill, North Carolina  27599-4105
                           Telephone No.:   (919) 966-3929
                           Telecopier No.:  (919) 962-0646
                           Attn.:    Mr. W. Mark Crowell
                                     Associate Vice Chancellor and Director

                                      -18-
<PAGE>

                  with copies to:

                           Auburn University
                           Office of Technology Transfer
                           309 Samford Hall
                           Auburn, Alabama  36849-5176
                           Telephone No.:  (334) 844-4977
                           Telecopier No.: (334) 844-5963
                           Attn.:    Ms. Jan Thornton
                                     Director

                  and to:

                           Duke University
                           Office of Science and Technology
                           454 Davison Building
                           Box 3664 DUMC
                           Durham, North Carolina  27710
                           Telephone No.:  (919) 681-6412
                           Telecopier No.: (919) 684-4595
                           Attn.:    Dr. Linda F. Abruzzini, Ph.D.
                                     Director, Research Resources and
                                     Patent Administration

                  and to:

                           Georgia State University Research Foundation, Inc.
                           University Plaza
                           Georgia State University
                           Atlanta, Georgia  30303
                           Telephone No.:  (404) 651-2569
                           Telecopier No.: (404) 651-2846
                           Attn.:    Mr. John D. Marshall, Jr.

                  If to Licensee, to:

                           Immtech International, Inc.
                           150 Fairway Drive, Suite 150
                           Vernon Hills, Illinois  60061
                           Telephone No.:  (847) 573-0033
                           Telecopier No.: (847) 573-8288
                           Attn.:    Mr. T. Stephen Thompson
                                     President & CEO

                                      -19-
<PAGE>

                  with copies to:

                           Immtech International, Inc.
                           One North End Avenue, Suite 1111
                           New York, New York  10282
                           Telephone No.:  (212) 791-2888
                           Telecopier No.: (212) 791-2917
                           Attn.:    Ms. Cecilia Chan
                                     Executive Vice President

                  and to:

                           Cadwalader, Wickersham & Taft
                           100 Maiden Lane
                           New York, New York  10038-4892
                           Telephone No.:  (212) 504-6000
                           Telecopier No.: (212) 504-6666
                           Attn.:    John F. Fritts, Esq.

22.      GOVERNING LAWS

      22.1 This Agreement shall be interpreted and construed in accordance with
the laws of the State of North Carolina.

23. COMPLETE AGREEMENT

      23.1 It is understood and agreed between the Licensors and Licensee that
this Agreement constitutes the entire agreement, both written and oral, between
the parties as to the licensing of the Future Compounds (and the Current
Compounds, if covered under this Agreement pursuant to Section 26.1), and that
all prior agreements relating to the Future Compounds (or the Current Compounds,
if covered under this Agreement pursuant to Section 26.1), either written or
oral, expressed or implied, shall be abrogated, canceled, and are null and void
and of no effect to the extent that they apply to the Future Compounds (and/or
the Current Compounds, if covered under this Agreement pursuant to Section
26.1). Notwithstanding the foregoing, the provisions of (a) Section 3(c),
Section 3(d) (last sentence only, as amended), and Section 5(b) of the 1997
Letter Agreement, (b) Section 1 of the Second Amendment, and (c) Section 2 of
the Third Amendment, are all incorporated by reference into this Agreement as if
fully set forth herein, except to the extent that they confer any rights,
responsibilities or obligations upon Pharm-Eco.

      23.2 Notwithstanding any other provision of this Agreement, Section 6 of
the 1997 Letter Agreement is incorporated by reference into this Agreement as if
fully set forth herein, except to the extent that it confers any rights,
responsibilities or obligations upon Pharm-Eco, subject to the following
additional provisions: Should [ ** ] then the Licensors shall have the option to
[ ** ]. The Licensors shall be entitled to exercise such option at any time up
until [ ** ] the date on which the Licensors deliver to Licensee written notice
of their exercise of the option.
--------
 **      Confidential Treatment Requested.

                                      -20-
<PAGE>

24. SEVERABILITY

      24.1 In the event that a court of competent jurisdiction holds any
provision of this Agreement to be invalid, such holding shall have no effect on
the remaining provisions of this Agreement, and they shall continue in full
force and effect.

25. RIGHTS TO APPOINT REPRESENTATIVES

      25.1 UNC is entitled, during the term of this Agreement, to designate (by
written notice to Licensee) one appropriate person as a non-voting observer (the
"Observer") of all meetings and other proceedings of Licensee's Board of
Directors. Licensee will provide to the Observer notice of all meetings of the
Board of Directors and a copy of all materials circulated among Licensee's
directors. The Observer and UNC shall be required, if requested by Licensee, to
execute an appropriate confidentiality and non-disclosure agreement covering
confidential information of Licensee; provided, however, that any such
confidentiality and non-disclosure agreement shall allow the Observer and UNC to
disclose such information to the other Licensors if such other Licensors first
agree in writing (and deliver such writing to Licensee) to become a party to
such agreement and to be bound by all of the terms and provisions of such
agreement as if they were an original party thereto.

26. APPLICABILITY TO CURRENT COMPOUNDS

      26.1 This Agreement and the Licenses shall be applicable to Current
Compounds, in addition to Future Compounds, upon the execution and delivery of
this Agreement. The parties hereto acknowledge the fact that that certain
License Agreement dated August 25, 1993, between UNC and Pharm-Eco (the
"Pharm-Eco License Agreement"), has previously been assigned, in its entirety,
to Licensee by Pharm-Eco. Upon the execution and delivery of this Agreement, (a)
each occurrence of the words "Future Compounds" (excluding the definition of
Future Compounds) shall be deemed to read as "Future Compounds and/or Current
Compounds" unless the context clearly indicates otherwise, (b) the definition of
"Patent Rights" set forth in this Agreement shall also include everything
contained within the definition of "Patent Rights" set forth in the Pharm-Eco
License Agreement, (c) the definition of "University Technology" set forth in
this Agreement shall also include everything contained within the definition of
"University Technology" set forth in the Pharm-Eco License Agreement, (d) this
Agreement shall supercede and serve in lieu of the Pharm-Eco License Agreement
with respect to all Current Compounds, and (e) the Pharm-Eco License Agreement
shall be hereby terminated in all respects and shall no longer be of any effect
whatsoever, and neither party thereto shall have thereunder any obligations of
any kind to the other.

27. CONFIDENTIALITY AND NON-DISCLOSURE OF INFORMATION

      27.1 Each of the Licensors, on the one hand, and Licensee, on the other
hand, agrees to accept and maintain the other's information, data, know-how,
samples and other disclosures
--------
 **      Confidential Treatment Requested.

                                      -21-

<PAGE>

hereunder or in connection with activities related to this Agreement
(collectively, "Information") on a confidential basis for a period of five (5)
years from the date of each such disclosure. The obligations of this Article 27
shall survive and continue for three (3) years after the expiration or any
termination of this Agreement. Specifically excluded from such confidential
treatment shall be Information which: (a) at the time of disclosure to the
receiving party, was already published, known publicly, or otherwise in the
public domain; (b) after disclosure to the receiving party, is published,
becomes known publicly, or otherwise becomes part of the public domain through
no fault or breach of the receiving party or any of its Affiliates; (c) the
receiving party can establish was in its possession prior to the time of
disclosure to it; or (d) after disclosure by the disclosing party, is made
available to the receiving party in good faith by a third party having no
obligation of confidentiality to the disclosing party.

28. ARBITRATION

      28.1 If there shall arise in the future any dispute between any of the
parties hereto arising out of or relating to this Agreement, such as is
contemplated by Section 3.6(b) with respect to Future Duke Licensed Products, or
to any aspect of the Licenses granted by this Agreement, the parties hereto
agree that if the parties to such dispute agree at such future time to submit
such dispute to arbitration, then such arbitration shall be a confidential and
binding arbitration before a tribunal under the Commercial Arbitration Rules of
the American Arbitration Association, and shall be held at a site mutually
agreeable to the parties to the arbitration. If the parties are unable to agree
upon a site, then the site shall be selected by the arbitration tribunal. The
arbitration tribunal shall consist of three (3) arbitrators. The party
requesting arbitration shall name an arbitrator selected by it in its request
for arbitration. The responding party shall name an arbitrator selected by it in
its answer or response to such request for arbitration. The two arbitrators so
named shall jointly select a third arbitrator, who shall be the chairman of the
tribunal and who shall have no prior or then existing relationship or business
arrangements or financial dealings with, or interests in, either of Licensee,
UNC or any other Licensor. The decision of the arbitration tribunal shall be
final, and judgment upon the award rendered by the arbitration tribunal may be
entered in any competent court having jurisdiction thereof for judicial
acceptance of such award and an order of enforcement. Each party hereto hereby
submits itself to the courts of the place of arbitration, but only for the entry
of judgement with respect to the decision of the arbitration tribunal. The
parties hereto agree that the arbitration tribunal may, in its sole discretion,
award reasonable costs and attorney's fees to the prevailing party, and may, in
its sole discretion, assess the costs of the arbitration against the
non-prevailing party.

29. SURVIVAL OF TERMS

      29.1 The provisions of Articles 6, 7, 9.3, 9.4, 9.5, 13, 14, 16, 17, 18,
19, 21, 22, 27, and 28 shall survive the expiration or termination of this
Agreement until the expiration of the appropriate statute of limitations for
such Article, except that Article 6 shall survive until eighteen (18) months
after the expiration or termination of the last contract requiring use of either
University Technology, Patent Rights, Licensed Products, Future Compounds, or
the Licenses.

                                      -22-
<PAGE>

30. TELECOPIER EXECUTION AND DELIVERY

      30.1 A facsimile, telecopy or other reproduction of this Agreement may be
executed by one or more parties hereto, and an executed copy of this Agreement
may be delivered by one or more parties hereto by facsimile, telecopy or similar
instantaneous electronic transmission device pursuant to which the signature of
or on behalf of such party can be seen, and such execution and delivery shall be
considered valid, binding and effective for all purposes. At the request of any
party hereto, all parties hereto agree to execute an original of this Agreement
as well as any facsimile, telecopy, or other reproduction hereof.

31. COUNTERPARTS

      31.1 This Agreement may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which, taken together, shall
constitute one and the same instrument.

32. GENERAL REPRESENTATIONS AND WARRANTIES

      32.1 Each party hereto represents and warrants to the other parties hereto
that (a) the execution and delivery of this Agreement has been duly authorized
and all actions necessary for the due execution and delivery of this Agreement
have been taken, in each case to the extent necessary to make this Agreement
valid and enforceable, and (b) this Agreement constitutes the legal, valid and
binding obligation of such party, and is enforceable against it in accordance
with its terms, and (c) the person signing this Agreement on behalf of such
party has the authority to do so on behalf of such party.

33. HEADINGS

      33.1 The Article and Section headings contained in this Agreement are for
reference purposes only and shall not affect in any manner the meaning or
interpretation of this Agreement.

      (REMAINDER OF PAGE INTENTIONALLY LEFT BLANK - SIGNATURE PAGE FOLLOWS)

                                      -23-
<PAGE>

         IN WITNESS WHEREOF, the Licensors and Licensee have each executed this
Agreement, in duplicate originals, by their respective officers hereunto duly
authorized, as of the day and year first above written.

THE UNIVERSITY OF NORTH CAROLINA              IMMTECH INTERNATIONAL, INC.
AT CHAPEL HILL

By: /s/  Tony G. Waldrop                      By:  /s/ T. Stephen Thompson
   ----------------------------------            -------------------------------
     Tony G. Waldrop                                T. Stephen Thompson
     Vice Chancellor for Research and               President & CEO
         Graduate Studies

GEORGIA STATE UNIVERSITY                       AUBURN UNIVERSITY
RESEARCH FOUNDATION, INC.

By: /s/ Charles Louis                          By:  /s/  Michael Moriarty
   ----------------------------------             ------------------------------
     Charles Louis                                  Michael Moriarty
     Chairman                                       Associate Provost and Vice
                                                    President for Research

DUKE UNIVERSITY

By:  /s/  Robert L. Taber, Ph.D.
   ----------------------------------
   Name:  Robert L. Taber, Ph.D.
   Title: Vice Chancellor, Science
          & Technology Development

Read and Understood:

By:  /s/ John Perfect, MD
    ---------------------------------
    Name:  John Perfect, MD
                                      -24-
<PAGE>

                                    EXHIBIT A
                                     TO THE
                                LICENSE AGREEMENT
                                -----------------
                         (dated as of January 28, 2002)

                                  PATENT RIGHTS
                                  -------------
                      (in existence as of January 24, 2002)

[ ** ]

--------
 **      Confidential Treatment Requested.

                                      A-1

<PAGE>

                                    EXHIBIT B
                                     TO THE
                                LICENSE AGREEMENT
                                -----------------
                         (dated as of January 28, 2002)

                              DESCRIPTIVE STATEMENT

Immtech International, Inc., is a biopharmaceutical company focused on the
discovery, development and commercialization of drugs for treating infectious
diseases. The company has an exclusive worldwide license to an anti-microbial
pharmaceutical platform that is licensed from a university consortium led by The
University of North Carolina at Chapel Hill and includes Duke University, Auburn
University, and Georgia State University. The platform is based on dication and
related chemical structures that work by binding in the minor groove of an
infectious organism's DNA, blocking life-sustaining enzymes, thereby killing the
infectious organism. The company, which works with the consortium on furthering
basic research, has active programs for the development of new drugs for fungal,
parasitic, bacterial and viral diseases.

                                      B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]